US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Contineum Therapeutics, INC.

14.06

-0.3100-2.16%

Post-market: 14.060.00000.00%19:34 EDT

Volume:122.84K

Turnover:1.73M

Market Cap:524.94M

PE:-7.35

High:14.45

Open:14.45

Low:13.78

Close:14.37

52wk High:16.91

52wk Low:5.07

Shares:37.34M

Float Shares:27.59M

Volume Ratio:0.67

T/O Rate:0.45%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.9138

EPS(LYR):-2.1700

ROE:-26.88%

ROA:-18.18%

PB:2.10

PE(LYR):-6.48

Loading ...

Overview Company News Filings

Contineum Q1 FY26 net loss narrows 9.6% to $14.5 million

Contineum CSO Daniel S. Lorrain sells USD 54,741 in common shares

Contineum Therapeutics grants 102,000 inducement stock options to new hires

Contineum Therapeutics announces annual shareholder meeting

Contineum reports positive Phase 1b data for PIPE-791 in chronic pain trial

Contineum Therapeutics Inc - Pipe-791 Phase 1B Trial Achieves Primary Endpoint for Safety and Tolerability

THOMSON REUTERS

Contineum Therapeutics Reports Positive Topline Data From Its Exploratory Pipe-791 Phase 1B Trial in Chronic Pain

THOMSON REUTERS

Contineum Therapeutics Inc - No Serious Adverse Events Reported in Pipe-791 Phase 1B Trial

THOMSON REUTERS

Contineum CSO Daniel S. Lorrain disposes of 4,170 shares for $56,025

Contineum Therapeutics grants 51,000-share inducement stock option under 2026 employment plan

Contineum Therapeutics Is Maintained at Outperform by Baird

RBC Capital Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM)

Stifel Nicolaus Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)

Contineum Therapeutics Inc - May Offer Class a Common Stock up to $100 Mln Through Leerink Partners - SEC Filing

THOMSON REUTERS

Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress

Contineum Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Contineum Therapeutics Q4 EPS $(0.49) Beats $(0.59) Estimate

Contineum Q4 FY2025 net loss totals USD 15.2 million as G&A expenses rise 8.0% to USD 4.4 million

Contineum Therapeutics Inc: Qtrly EPS $-0.49

THOMSON REUTERS

Press Release: Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CTNM/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTNM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTNM\",,,,,undefined,":{"symbol":"CTNM","market":"US","secType":"STK","nameCN":"Contineum Therapeutics, INC.","latestPrice":14.06,"timestamp":1784923200000,"preClose":14.37,"halted":0,"volume":122843,"hourTrading":{"tag":"盘后","latestPrice":14.06,"preClose":14.06,"latestTime":"19:34 EDT","volume":4226,"amount":59417.56,"timestamp":1784936046149,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.021572720946416057,"floatShares":27590800,"shares":37336000,"eps":-1.91379,"marketStatus":"Market Closed","change":-0.31,"latestTime":"07-24 16:00:00 EDT","open":14.45,"high":14.45,"low":13.78,"amount":1733689.278307,"amplitude":0.046625,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.91379,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"listingDate":1712289600000,"exchange":"NASDAQ","adjPreClose":14.37,"postHourTrading":{"tag":"盘后","latestPrice":14.06,"preClose":14.06,"latestTime":"19:34 EDT","volume":4226,"amount":59417.56,"timestamp":1784936046149,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6738293573799882,"impliedVol":1.2994,"impliedVolPercentile":0.6494},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTNM\",,,,,undefined,":{"symbol":"CTNM","floatShares":27590800,"roa":"-18.18%","roe":"-26.88%","lyrEps":-2.169999,"volumeRatio":0.6738293573799882,"shares":37336000,"dividePrice":0,"high":14.45,"amplitude":0.046625,"preClose":14.37,"low":13.78,"week52Low":5.07,"pbRate":"2.10","week52High":16.91,"institutionHeld":0,"latestPrice":14.06,"eps":-1.91379,"divideRate":0,"volume":122843,"delay":0,"ttmEps":-1.91379,"open":14.45,"prevYearClose":11.43,"prevWeekClose":14.23,"prevMonthClose":16.39,"prevQuarterClose":16.39,"fiveDayClose":14.23,"twentyDayClose":13.36,"sixtyDayClose":12.54},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTNM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-05","symbol":"CTNM","fiscalQuarterEnding":"2026/03","expectedEps":-0.55,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1777953600000,"reportTimeType":"post","actualEps":-0.39},{"market":"US","date":"2026-03-05","symbol":"CTNM","fiscalQuarterEnding":"2025/12","expectedEps":-0.5,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-10-30","symbol":"CTNM","fiscalQuarterEnding":"2025/09","expectedEps":-0.58,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1761796800000,"reportTimeType":"post","actualEps":-0.45},{"market":"US","date":"2025-08-05","symbol":"CTNM","fiscalQuarterEnding":"2025/06","expectedEps":-0.56,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"post","actualEps":-0.62},{"market":"US","date":"2025-05-14","symbol":"CTNM","fiscalQuarterEnding":"2025/03","expectedEps":-0.56,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.62}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTNM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTNM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5714,"buy":0.2857,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2857,"analysts":7,"updateTime":1767931200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CTNM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CTNM","date":"2026-07-24","current":-7.346679,"percent":0.24552,"low":-16.425726,"twenty":-9.67595,"median":-5.858705,"eighty":-2.342386,"high":28.322904,"avg":-3.748341,"sd":10.125998,"marketCap":537242237},"quantilePoints":[{"date":"2024-04-05","current":16.281367,"twenty":16.281367,"median":16.281367,"eighty":16.281367,"marketCap":369912656},{"date":"2024-04-12","current":17.609251,"twenty":16.281367,"median":16.569509,"eighty":16.868158,"marketCap":400082176},{"date":"2024-04-19","current":17.122563,"twenty":16.281367,"median":16.868158,"eighty":17.144685,"marketCap":389024629},{"date":"2024-04-26","current":17.686678,"twenty":16.315104,"median":17.089379,"eighty":17.59819,"marketCap":401841332},{"date":"2024-05-03","current":16.48102,"twenty":16.48102,"median":17.122563,"eighty":17.59819,"marketCap":374448771},{"date":"2024-05-10","current":17.719862,"twenty":16.38147,"median":17.105971,"eighty":17.59819,"marketCap":402595255},{"date":"2024-05-17","current":16.547386,"twenty":16.392531,"median":17.100441,"eighty":17.487579,"marketCap":375956618},{"date":"2024-05-24","current":17.819411,"twenty":16.48102,"median":17.133624,"eighty":17.59819,"marketCap":404857026},{"date":"2024-05-31","current":20.173009,"twenty":16.534113,"median":17.172337,"eighty":17.68889,"marketCap":385849140},{"date":"2024-06-07","current":21.67926,"twenty":16.768608,"median":17.354846,"eighty":18.209439,"marketCap":414659209},{"date":"2024-06-14","current":22.311348,"twenty":16.85046,"median":17.388029,"eighty":20.619504,"marketCap":426749148},{"date":"2024-06-21","current":26.466988,"twenty":16.894704,"median":17.487579,"eighty":21.17897,"marketCap":506234071},{"date":"2024-06-28","current":25.216261,"twenty":16.921251,"median":17.542884,"eighty":21.517876,"marketCap":482311425},{"date":"2024-07-05","current":27.018383,"twenty":16.987617,"median":17.609251,"eighty":21.78147,"marketCap":516780614},{"date":"2024-07-12","current":28.242212,"twenty":17.042923,"median":17.692208,"eighty":22.916538,"marketCap":540188796},{"date":"2024-07-15","current":27.932893,"twenty":17.049559,"median":17.697739,"eighty":23.766494,"marketCap":534272442},{"date":"2024-08-02","current":26.224911,"twenty":17.056196,"median":17.697739,"eighty":24.100021,"marketCap":501603882},{"date":"2024-08-09","current":22.338245,"twenty":17.08938,"median":17.819411,"eighty":24.409341,"marketCap":427263614},{"date":"2024-08-16","current":-15.206885,"twenty":17.023013,"median":17.769636,"eighty":24.100021,"marketCap":478195700},{"date":"2024-08-23","current":-14.92058,"twenty":16.547386,"median":17.697739,"eighty":23.683112,"marketCap":469192554},{"date":"2024-08-30","current":-15.468649,"twenty":16.315104,"median":17.614781,"eighty":23.293101,"marketCap":486427149},{"date":"2024-09-06","current":-14.511573,"twenty":15.417858,"median":17.570537,"eighty":22.830467,"marketCap":456330916},{"date":"2024-09-13","current":-14.765157,"twenty":-14.025672,"median":17.410151,"eighty":22.682531,"marketCap":464305131},{"date":"2024-09-20","current":-16.425726,"twenty":-14.408503,"median":17.365907,"eighty":22.459283,"marketCap":516523382},{"date":"2024-09-27","current":-15.272326,"twenty":-14.745525,"median":17.19999,"eighty":22.405488,"marketCap":480253562},{"date":"2024-10-04","current":-14.421591,"twenty":-14.887859,"median":17.133624,"eighty":22.351694,"marketCap":453501355},{"date":"2024-10-11","current":-13.521775,"twenty":-14.788061,"median":17.100441,"eighty":22.316727,"marketCap":425205752},{"date":"2024-10-18","current":-13.480875,"twenty":-14.745525,"median":17.039604,"eighty":22.010098,"marketCap":423919588},{"date":"2024-10-25","current":-13.309092,"twenty":-14.662087,"median":16.868158,"eighty":21.934785,"marketCap":418517700},{"date":"2024-10-31","current":-14.004404,"twenty":-14.595828,"median":16.547386,"eighty":21.78147,"marketCap":440382485},{"date":"2024-11-08","current":-13.455721,"twenty":-14.532841,"median":16.387,"eighty":21.655052,"marketCap":477166769},{"date":"2024-11-15","current":-13.193473,"twenty":-14.477216,"median":16.281367,"eighty":21.566291,"marketCap":467866942},{"date":"2024-11-22","current":-10.423934,"twenty":-14.434679,"median":15.167037,"eighty":21.517876,"marketCap":369653551},{"date":"2024-11-29","current":-10.838275,"twenty":-14.411775,"median":-9.795154,"eighty":21.388769,"marketCap":384346893},{"date":"2024-12-06","current":-10.358512,"twenty":-14.347406,"median":-10.271282,"eighty":21.17897,"marketCap":367333550},{"date":"2024-12-13","current":-10.031401,"twenty":-14.270231,"median":-10.358512,"eighty":21.154762,"marketCap":355733543},{"date":"2024-12-20","current":-9.70429,"twenty":-14.217087,"median":-10.242206,"eighty":20.950342,"marketCap":344133536},{"date":"2024-12-27","current":-10.569317,"twenty":-14.14183,"median":-10.271282,"eighty":20.635643,"marketCap":374809110},{"date":"2025-01-03","current":-10.525702,"twenty":-14.135286,"median":-10.358512,"eighty":20.603366,"marketCap":373262442},{"date":"2025-01-10","current":-9.718828,"twenty":-14.073857,"median":-10.358512,"eighty":20.25908,"marketCap":344649092},{"date":"2025-01-17","current":-9.071876,"twenty":-14.047944,"median":-10.256744,"eighty":19.850241,"marketCap":321706856},{"date":"2025-01-24","current":-8.19958,"twenty":-14.045305,"median":-10.209494,"eighty":18.599466,"marketCap":290773505},{"date":"2025-01-31","current":-7.429052,"twenty":-14.035488,"median":-10.009594,"eighty":17.759682,"marketCap":263449044},{"date":"2025-02-07","current":-6.883867,"twenty":-14.024036,"median":-9.925999,"eighty":17.706588,"marketCap":244115699},{"date":"2025-02-14","current":-5.589962,"twenty":-14.010948,"median":-9.718828,"eighty":17.697739,"marketCap":198231228},{"date":"2025-02-21","current":-5.742614,"twenty":-13.988044,"median":-9.667944,"eighty":17.693315,"marketCap":203644564},{"date":"2025-02-28","current":-5.19016,"twenty":-13.940599,"median":-9.518928,"eighty":17.660132,"marketCap":184053442},{"date":"2025-03-07","current":-3.942751,"twenty":-13.847345,"median":-9.071876,"eighty":17.615888,"marketCap":166612775},{"date":"2025-03-14","current":-4.371311,"twenty":-13.716463,"median":-8.19958,"eighty":17.604827,"marketCap":184722859},{"date":"2025-03-21","current":-4.377433,"twenty":-13.63957,"median":-8.126889,"eighty":17.576068,"marketCap":184981575},{"date":"2025-03-28","current":-4.561102,"twenty":-13.619937,"median":-7.567165,"eighty":17.520762,"marketCap":192743040},{"date":"2025-04-04","current":-3.75296,"twenty":-13.617995,"median":-7.116479,"eighty":17.456608,"marketCap":158592595},{"date":"2025-04-11","current":-2.528503,"twenty":-13.600664,"median":-6.847522,"eighty":17.401302,"marketCap":106849497},{"date":"2025-04-17","current":-2.681561,"twenty":-13.574128,"median":-6.436815,"eighty":17.385817,"marketCap":113317384},{"date":"2025-04-25","current":-2.767272,"twenty":-13.55286,"median":-5.742614,"eighty":17.372544,"marketCap":116939401},{"date":"2025-05-02","current":-2.430547,"twenty":-13.541408,"median":-5.640845,"eighty":17.334936,"marketCap":102710049},{"date":"2025-05-09","current":-2.418302,"twenty":-13.513595,"median":-5.553616,"eighty":17.244235,"marketCap":102192618},{"date":"2025-05-16","current":-2.045592,"twenty":-13.477603,"median":-5.430041,"eighty":17.188929,"marketCap":101933903},{"date":"2025-05-23","current":-2.030017,"twenty":-13.462755,"median":-5.321004,"eighty":17.144685,"marketCap":101157756},{"date":"2025-05-30","current":-1.853493,"twenty":-13.455721,"median":-5.117468,"eighty":17.144685,"marketCap":92361429},{"date":"2025-06-06","current":-2.154621,"twenty":-13.448154,"median":-4.770625,"eighty":17.122563,"marketCap":107366928},{"date":"2025-06-13","current":-2.40383,"twenty":-13.399073,"median":-4.628447,"eighty":17.122563,"marketCap":119785271},{"date":"2025-06-20","current":-1.895028,"twenty":-13.379975,"median":-4.585591,"eighty":17.104865,"marketCap":94431153},{"date":"2025-06-27","current":-2.081935,"twenty":-13.328858,"median":-4.536848,"eighty":17.091592,"marketCap":103744911},{"date":"2025-07-03","current":-2.014441,"twenty":-13.312364,"median":-4.445597,"eighty":17.06947,"marketCap":100381610},{"date":"2025-07-11","current":-2.092319,"twenty":-13.309092,"median":-4.377433,"eighty":17.036286,"marketCap":104262342},{"date":"2025-07-18","current":-1.993674,"twenty":-13.304184,"median":-4.325394,"eighty":16.96992,"marketCap":99346748},{"date":"2025-07-25","current":-2.959359,"twenty":-13.281279,"median":-4.150909,"eighty":16.894704,"marketCap":147467829},{"date":"2025-08-01","current":-3.063196,"twenty":-13.22336,"median":-4.01928,"eighty":16.841612,"marketCap":152642139},{"date":"2025-08-08","current":-3.062072,"twenty":-13.164683,"median":-3.75296,"eighty":16.657997,"marketCap":174115524},{"date":"2025-08-15","current":-3.58032,"twenty":-12.764301,"median":-3.489183,"eighty":16.507566,"marketCap":203584157},{"date":"2025-08-22","current":-4.951297,"twenty":-12.507357,"median":-3.639499,"eighty":16.427927,"marketCap":281540625},{"date":"2025-08-29","current":-4.956228,"twenty":-11.906412,"median":-3.948873,"eighty":16.385894,"marketCap":281821044},{"date":"2025-09-05","current":-5.419796,"twenty":-11.370375,"median":-4.039068,"eighty":16.354924,"marketCap":308180426},{"date":"2025-09-12","current":-5.824184,"twenty":-11.101417,"median":-4.150909,"eighty":16.301609,"marketCap":331174779},{"date":"2025-09-19","current":-6.115147,"twenty":-10.938589,"median":-4.325394,"eighty":16.232919,"marketCap":347719498},{"date":"2025-09-26","current":-5.355685,"twenty":-10.838275,"median":-4.374303,"eighty":15.930178,"marketCap":304534979},{"date":"2025-10-03","current":-5.301438,"twenty":-10.774307,"median":-4.411924,"eighty":15.250644,"marketCap":301450371},{"date":"2025-10-10","current":-5.996789,"twenty":-10.666723,"median":-4.53049,"eighty":8.143309,"marketCap":340989443},{"date":"2025-10-17","current":-6.144737,"twenty":-10.617293,"median":-4.573346,"eighty":-1.787038,"marketCap":349402011},{"date":"2025-10-24","current":-5.483906,"twenty":-10.566409,"median":-4.58636,"eighty":-1.820784,"marketCap":311825872},{"date":"2025-10-31","current":-5.197875,"twenty":-10.55914,"median":-4.692731,"eighty":-1.833764,"marketCap":295561573},{"date":"2025-11-07","current":-5.410266,"twenty":-10.548963,"median":-4.832939,"eighty":-1.851935,"marketCap":321299446},{"date":"2025-11-14","current":-5.356212,"twenty":-10.534425,"median":-4.919242,"eighty":-1.870107,"marketCap":318089369},{"date":"2025-11-21","current":-6.004854,"twenty":-10.522794,"median":-4.956228,"eighty":-1.897105,"marketCap":356610284},{"date":"2025-11-28","current":-5.439749,"twenty":-10.511164,"median":-5.1056,"eighty":-1.907489,"marketCap":323050396},{"date":"2025-12-05","current":-5.395524,"twenty":-10.480633,"median":-5.127036,"eighty":-1.940717,"marketCap":320423970},{"date":"2025-12-12","current":-6.422541,"twenty":-10.474818,"median":-5.15474,"eighty":-1.961484,"marketCap":381415418},{"date":"2025-12-19","current":-5.596996,"twenty":-10.473364,"median":-5.194017,"eighty":-1.980175,"marketCap":332388800},{"date":"2025-12-26","current":-6.230896,"twenty":-10.467549,"median":-5.225482,"eighty":-1.988482,"marketCap":370034239},{"date":"2026-01-02","current":-5.616652,"twenty":-10.432657,"median":-5.250562,"eighty":-1.988482,"marketCap":333556100},{"date":"2026-01-09","current":-5.640545,"twenty":-10.418119,"median":-5.238277,"eighty":-1.992636,"marketCap":334975047},{"date":"2026-01-16","current":-7.282885,"twenty":-10.370143,"median":-5.311221,"eighty":-1.993674,"marketCap":432508676},{"date":"2026-01-23","current":-7.76882,"twenty":-10.358512,"median":-5.340862,"eighty":-1.996789,"marketCap":461366940},{"date":"2026-01-30","current":-8.980584,"twenty":-10.345428,"median":-5.356212,"eighty":-2.000423,"marketCap":533329955},{"date":"2026-02-06","current":-8.906771,"twenty":-10.297451,"median":-5.376869,"eighty":-2.009249,"marketCap":528946421},{"date":"2026-02-13","current":-9.152815,"twenty":-10.253836,"median":-5.386426,"eighty":-2.014441,"marketCap":543558201},{"date":"2026-02-20","current":-9.841736,"twenty":-10.233483,"median":-5.400438,"eighty":-2.020671,"marketCap":584471184},{"date":"2026-02-27","current":-9.706412,"twenty":-10.211675,"median":-5.415031,"eighty":-2.032093,"marketCap":576434705},{"date":"2026-03-06","current":-8.494648,"twenty":-10.131715,"median":-5.429659,"eighty":-2.035208,"marketCap":504471690},{"date":"2026-03-13","current":-8.627788,"twenty":-10.022678,"median":-5.439635,"eighty":-2.037285,"marketCap":517477458},{"date":"2026-03-20","current":-7.538421,"twenty":-10.003778,"median":-5.449385,"eighty":-2.042477,"marketCap":452139395},{"date":"2026-03-27","current":-8.497064,"twenty":-9.968886,"median":-5.459248,"eighty":-2.051822,"marketCap":509636891},{"date":"2026-04-02","current":-8.372565,"twenty":-9.928179,"median":-5.466715,"eighty":-2.065321,"marketCap":502169684},{"date":"2026-04-10","current":-7.986617,"twenty":-9.906238,"median":-5.479061,"eighty":-2.081935,"marketCap":479021341},{"date":"2026-04-17","current":-8.27919,"twenty":-9.836054,"median":-5.512918,"eighty":-2.084012,"marketCap":496569278},{"date":"2026-04-24","current":-7.731394,"twenty":-9.810397,"median":-5.553616,"eighty":-2.100626,"marketCap":463713567},{"date":"2026-05-01","current":-7.980392,"twenty":-9.782709,"median":-5.593479,"eighty":-2.134892,"marketCap":478647981},{"date":"2026-05-08","current":-9.346147,"twenty":-9.716345,"median":-5.597332,"eighty":-2.142161,"marketCap":546226206},{"date":"2026-05-15","current":-9.090076,"twenty":-9.706412,"median":-5.616855,"eighty":-2.169158,"marketCap":531260417},{"date":"2026-05-22","current":-9.192428,"twenty":-9.705988,"median":-5.636308,"eighty":-2.233537,"marketCap":537242237},{"date":"2026-05-29","current":-8.51435,"twenty":-9.70429,"median":-5.640545,"eighty":-2.258458,"marketCap":497612677},{"date":"2026-06-05","current":-7.893845,"twenty":-9.687959,"median":-5.659308,"eighty":-2.268842,"marketCap":461347892},{"date":"2026-06-12","current":-7.586791,"twenty":-9.667944,"median":-5.675619,"eighty":-2.28961,"marketCap":443402431},{"date":"2026-06-18","current":-7.7787,"twenty":-9.662129,"median":-5.714931,"eighty":-2.297916,"marketCap":454618344},{"date":"2026-06-26","current":-8.546335,"twenty":-9.628373,"median":-5.735345,"eighty":-2.299993,"marketCap":499481996},{"date":"2026-07-02","current":-9.748963,"twenty":-9.663583,"median":-5.762064,"eighty":-2.315568,"marketCap":569768385},{"date":"2026-07-10","current":-9.883299,"twenty":-9.694491,"median":-5.794595,"eighty":-2.329935,"marketCap":577619524},{"date":"2026-07-17","current":-8.962137,"twenty":-9.694491,"median":-5.82665,"eighty":-2.336264,"marketCap":523783141},{"date":"2026-07-24","current":-9.192428,"twenty":-9.67595,"median":-5.858705,"eighty":-2.342386,"marketCap":537242237}],"updateTime":1785096881476},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTNM\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633929741","title":"Contineum Q1 FY26 net loss narrows 9.6% to $14.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633929741","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633929741?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:19","pubTimestamp":1778012372,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics reported a net loss of USD 14.5 million, narrowing from USD 16 million, or USD 0.39 per share versus USD 0.62 per share.Research and development expense fell 15% to USD 11.6 million, while general and administrative costs rose 20% to USD 5.3 million.Cash, cash equivalents and marketable securities totaled USD 246.3 million, with cash runway projected through mid-2029.Positive topline data were reported from an exploratory Phase 1b chronic pain trial of PIPE-791, while dosing began in the PROPEL-IPF global Phase 2 study in first quarter 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL3XsbwJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632628757","title":"Contineum CSO Daniel S. Lorrain sells USD 54,741 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2632628757","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632628757?lang=en_us&edition=fundamental","pubTime":"2026-05-02 05:43","pubTimestamp":1777671806,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain sold 4,170 shares of Class A common stock on May 1, 2026.Sales were reported at weighted average prices of $13.06 and $13.84.Lorrain reported 143,542 shares owned directly following transactions.Filing also showed 6,842 shares held indirectly by spouse.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDLbLqCyc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Contineum CSO Daniel S. Lorrain sells USD 54,741 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632642087","title":"Contineum Therapeutics grants 102,000 inducement stock options to new hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2632642087","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632642087?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:05","pubTimestamp":1777665917,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics granted inducement equity awards to two new non-executive employees under its 2026 Employment Inducement Equity Incentive Plan.Each hire received a non-qualified stock option covering 51,000 shares of Class A common stock.Grants were dated April 28, 2026, and April 30, 2026.Options carry an exercise price equal to closing share price on each grant date.Vesting runs over four years, starting with 25% after one year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on May 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL7S29LN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632669810","title":"Contineum Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2632669810","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632669810?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:17","pubTimestamp":1777580258,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics will hold 2026 annual stockholders meeting virtually on June 26, 2026.Vote scheduled on election of three Class II directors to serve until 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL5Zn6zL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632866629","title":"Contineum reports positive Phase 1b data for PIPE-791 in chronic pain trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2632866629","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632866629?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:17","pubTimestamp":1777580235,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics reported positive topline results from exploratory Phase 1b trial of PIPE-791 in chronic osteoarthritis pain or chronic low back pain.Results have been presented as topline data, with trial meeting primary endpoint on safety and tolerability.Exploratory efficacy readouts showed encouraging trends in pain and functional patient-reported outcomes, generally favoring PIPE-791 over placebo.PIPE-791 was tested as once-daily 10 mg oral dose in 43 patients across two 4-week crossover treatment periods.Data supported further evaluation of PIPE-791 in chronic pain, with Contineum weighing next clinical development steps.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original cont","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL8cCGkw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632982665","title":"Contineum Therapeutics Inc - Pipe-791 Phase 1B Trial Achieves Primary Endpoint for Safety and Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2632982665","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632982665?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:05","pubTimestamp":1777579502,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUA2RLKHT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632366593","title":"Contineum Therapeutics Reports Positive Topline Data From Its Exploratory Pipe-791 Phase 1B Trial in Chronic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2632366593","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632366593?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:05","pubTimestamp":1777579502,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUA2RLKHT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632106665","title":"Contineum Therapeutics Inc - No Serious Adverse Events Reported in Pipe-791 Phase 1B Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2632106665","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632106665?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:05","pubTimestamp":1777579502,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUA2RLKHT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625602929","title":"Contineum CSO Daniel S. Lorrain disposes of 4,170 shares for $56,025","url":"https://stock-news.laohu8.com/highlight/detail?id=2625602929","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625602929?lang=en_us&edition=fundamental","pubTime":"2026-04-07 05:44","pubTimestamp":1775511843,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain sold 4,170 Class A common shares on April 6, 2026 at $13.43 per share.Direct holdings fell to 147,712 shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL3y5Nt3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Contineum CSO Daniel S. Lorrain disposes of 4,170 shares for $56,025","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619109951","title":"Contineum Therapeutics grants 51,000-share inducement stock option under 2026 employment plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2619109951","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619109951?lang=en_us&edition=fundamental","pubTime":"2026-03-14 04:05","pubTimestamp":1773432338,"startTime":"0","endTime":"0","summary":"Contineum said its board compensation committee granted a non-qualified stock option covering 51,000 shares of Class A common stock to one new non-executive employee under its 2026 Employment Inducement Equity Incentive Plan. The option’s exercise price will equal the Class A common stock closing price on the grant date. The award vests over four years, with 25% vesting after one year and the remainder vesting monthly over the next 36 months. The option has a 10-year term.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL4vMWDj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617680151","title":"Contineum Therapeutics Is Maintained at Outperform by Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2617680151","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617680151?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:52","pubTimestamp":1772801520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CTNM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2026 07:52 ET (12:52 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617820626","title":"RBC Capital Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617820626","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617820626?lang=en_us&edition=fundamental","pubTime":"2026-03-06 19:56","pubTimestamp":1772798208,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Matthew Hedberg from RBC Capital maintained a Buy rating on Contineum Therapeutics, Inc. Class A, with a price targ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-contineum-therapeutics-inc-class-a-ctnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-contineum-therapeutics-inc-class-a-ctnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128525929.USD","LU0708994859.HKD","BK4207","LU0310800379.SGD","CTNM","LU0029864427.USD","LU1267930573.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617682019","title":"Stifel Nicolaus Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617682019","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617682019?lang=en_us&edition=fundamental","pubTime":"2026-03-06 19:56","pubTimestamp":1772798184,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Contineum Therapeutics, Inc. Class A today and set a price target of $29.00. Accord...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-contineum-therapeutics-inc-class-a-ctnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-contineum-therapeutics-inc-class-a-ctnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTNM","SF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617718545","title":"Contineum Therapeutics Inc - May Offer Class a Common Stock up to $100 Mln Through Leerink Partners - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617718545","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617718545?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:48","pubTimestamp":1772747285,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nFWN3ZT0U3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617797835","title":"Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2617797835","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617797835?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:36","pubTimestamp":1772746598,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Contineum Therapeutics, Inc. Class A ( ($CTNM) ). Contineum Therapeutics amended its existing at-the-market equ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/contineum-therapeutics-expands-atm-facility-highlights-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/contineum-therapeutics-expands-atm-facility-highlights-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CTNM","BK4097","LU2065732104.USD","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617579638","title":"Contineum Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2617579638","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617579638?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:32","pubTimestamp":1772746361,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryContineum Therapeutics Inc CTNM.OQ reported a quarterly adjusted loss of 49 cents per share for the quart","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL8N3ZT2TV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617577576","title":"Contineum Therapeutics Q4 EPS $(0.49) Beats $(0.59) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2617577576","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617577576?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:13","pubTimestamp":1772745220,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.59) by 16.67 percent. This is a 12.5 percent increase over losses of $(0.56) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51083624/contineum-therapeutics-q4-eps-0-49-beats-0-59-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617575053","title":"Contineum Q4 FY2025 net loss totals USD 15.2 million as G&A expenses rise 8.0% to USD 4.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617575053","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617575053?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:06","pubTimestamp":1772744779,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics reported Q4 2025 results, posting a net loss of USD 15.2 million and R&D expenses of USD 12.8 million , while G&A expenses rose to USD 4.4 million . Cash, cash equivalents and marketable securities totaled USD 262.9 million at December 31, 2025, and the company said its cash resources are sufficient to fund planned operations through mid-2029; during Q4 it completed an upsized public offering generating net proceeds of USD 93.0 million from the issuance of approximately 8.1 million Class A shares at USD 12.25. On the business side, Contineum said it has initiated patient dosing in PROPEL-IPF, a global Phase 2 trial of once-daily oral PIPE-791 in idiopathic pulmonary fibrosis . The company also reiterated it expects topline data in Q2 2026 from an exploratory Phase 1b PIPE-791 trial in chronic osteoarthritis pain or chronic lower back pain, and noted Johnson & Johnson began recruiting in December 2024 for the Phase 2 Moonlight-1 trial of PIPE-307/JNJ-89495120 in m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL3glqSn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4239.USD","LU1674673691.USD","IE00B2B36J28.USD","LU2347655156.SGD","LU0466842654.USD","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","LU2471134796.USD","LU2505996509.AUD","LU1929549753.HKD","LU0345770308.USD","LU0203347892.USD","LU1244550494.USD","LU0289739699.SGD","IE0001KFT4U8.USD","LU1894683264.USD","LU2133065610.SGD","IE00B3T34201.USD","LU0234572021.USD","LU1066051225.USD","IE0034235303.USD","LU1894683348.USD","LU0882574055.USD","BK4581","LU2112291526.USD","LU0070217475.USD","LU1935042991.SGD","IE00BGHQF631.EUR","LU0795875169.SGD","LU2592432038.USD","IE00B3PB1722.GBP","LU1983299246.USD","LU2471134879.HKD","LU1066053197.SGD","JNJ","IE00BVYPNV92.GBP","CTNM","BK4550","LU0792757196.USD","BK4568","LU1674673428.USD","LU1718418525.SGD","IE00B42XCP33.USD","LU1059921491.USD","LU0912757837.SGD","LU0114720955.EUR","BK4504","SG9999002232.USD","LU0058720904.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617579975","title":"Contineum Therapeutics Inc: Qtrly EPS $-0.49","url":"https://stock-news.laohu8.com/highlight/detail?id=2617579975","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617579975?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:05","pubTimestamp":1772744701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA36LXZN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617575774","title":"Press Release: Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2617575774","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617575774?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:05","pubTimestamp":1772744700,"startTime":"0","endTime":"0","summary":"- Patient dosing initiated in PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis . - Topline data from the exploratory PIPE-791 Phase 1b trial in patients with chronic pain is expected in the second quarter of 2026. Contineum Therapeutics, Inc.  , a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology  indications, today reported its fourth-quarter 2025 financial results and affirmed its key clinical development milestones.\"We're off to a strong start in 2026, having recently dosed the first patient in our global Phase 2 idiopathic pulmonary fibrosis  trial, \" said Carmine Stengone, CEO, Contineum Therapeutics. \"IPF is a devastating disease that profoundly impacts patients and their families. We're urgently advancing PIPE-791 with the goal of developing a transformative therapy that we believe could address the limitations of curren","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0001KFT4U8.USD","JNJ","LU2505996681.GBP","LU2471134796.USD","LU0345769631.USD","LU0345770993.USD","IE00BN8TJ469.HKD","LU2129689605.HKD","LU2129689431.USD","LU2129689514.USD","LU1196500208.SGD","LU2133065610.SGD","LU0432979614.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4559","IE00B2B36J28.USD","LU1718418525.SGD","BK4550","IE00BVYPNV92.GBP","LU2602419157.SGD","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","LU1066053197.SGD","LU1023059063.AUD","CTNM","LU0345769128.USD","LU1267930813.SGD","LU0795875086.SGD","IE00BFTCPJ56.SGD","BK4568","IE00BSNM7G36.USD","LU2468319806.SGD","LU2592432038.USD","LU1162221912.USD","IE0002270589.USD","IE00B3PB1722.GBP","LU2430703095.HKD","LU1894683264.USD","LU0124676726.USD","LU0795875169.SGD","LU0689626769.HKD","LU0058720904.USD","LU0640476718.USD","LU2471134879.HKD","LU1935042991.SGD","LU0098860793.USD","LU0985320562.USD","BK4588","LU0320765646.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":57,"code":"91000000","status":"200"}]}}